Omniox key facts
as of Oct 2026- Developer of novel biologics designed to provide meaningful therapeutic benefits to patients.
- Omniox is valued at approximately $150.0M as of Oct 2026, set at its later-stage round, Nov 2023; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $119.7M across 5 recorded rounds; the latest was Debt ($24.1M) in Aug 2016.
- Notable investors include Plug and Play Tech Center, National Institutes of Health, University of California, Samsara BioCapital, Casdin Capital — 18 tracked in total.
- Omniox has filed 4 Form Ds with the SEC since 2012, most recently Jul 2016 ($4.7M sold to 29 investors).
- Status: Privately Held (backing).
Valued at $150.0M at its later-stage round, Nov 2023. Nothing has traded since.
- ·The complete investor list: 18 names
- ·Watch Omniox: the Monday email on marks, rounds and moves
Omniox funding rounds
5 roundsWho backs Omniox
18+Omniox valuation
Omniox was valued at $150 million at its later-stage round in Nov 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Omniox raised?
Omniox has raised $120 million in total; 5 of its rounds are on record, from 2012 on. The largest on record was a $6.6 million early-stage round in Jun 2014; the most recent was a $24.1 million debt round in Aug 2016.
Omniox has filed 4 Form Ds with the SEC since 2012, most recently in Jul 2016 ($4.7 million sold to 29 investors).
Omniox investors
18 investors are on record for Omniox, including Plug and Play Tech Center, National Institutes of Health, University of California and Samsara BioCapital. The debt round in Aug 2016 drew 93 investors.
About Omniox
Developer of novel biologics designed to provide meaningful therapeutic benefits to patients. The company's biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes by specifically oxygenating pathologically hypoxic tissues they restore normal tissue function with the potential for improved outcomes and patient cures, enabling healthcare professionals to pioneer innovative oxygen-based therapies that restore health to patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2006
- Employees
- 3
- Website
- omniox.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.